U.S. markets closed
  • S&P Futures

    3,443.75
    +21.00 (+0.61%)
     
  • Dow Futures

    28,254.00
    +154.00 (+0.55%)
     
  • Nasdaq Futures

    11,736.25
    +86.00 (+0.74%)
     
  • Russell 2000 Futures

    1,622.90
    +11.60 (+0.72%)
     
  • Crude Oil

    40.72
    -0.11 (-0.27%)
     
  • Gold

    1,906.10
    -5.60 (-0.29%)
     
  • Silver

    24.53
    -0.16 (-0.66%)
     
  • EUR/USD

    1.1776
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.7610
    +0.0170 (+2.28%)
     
  • Vix

    29.18
    +1.77 (+6.46%)
     
  • GBP/USD

    1.2947
    +0.0006 (+0.05%)
     
  • USD/JPY

    105.5920
    +0.1620 (+0.15%)
     
  • BTC-USD

    11,731.09
    +674.08 (+6.10%)
     
  • CMC Crypto 200

    238.78
    +5.11 (+2.19%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,631.96
    -39.17 (-0.17%)
     

Insider Buying: Robert Ingram Just Spent US$152k On Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares

Simply Wall St
·3 mins read

Investors who take an interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) should definitely note that insider Robert Ingram recently paid US$30.46 per share to buy US$152k worth of the stock. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

Check out our latest analysis for Black Diamond Therapeutics

Black Diamond Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Director Rajeev Shah for US$2.6m worth of shares, at about US$19.00 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$30.67. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

Black Diamond Therapeutics insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Black Diamond Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Black Diamond Therapeutics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Black Diamond Therapeutics insiders own 3.0% of the company, worth about US$33m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Black Diamond Therapeutics Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Black Diamond Therapeutics we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 3 warning signs for Black Diamond Therapeutics you should be aware of, and 1 of them is a bit concerning.

Of course Black Diamond Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.